Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)

NCT03232593 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03232593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03232593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
November 29, 2017
Completion date
August 12, 2022
Enrollment
1,758 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, hepatocellular carcinoma, small cell lung carcinoma, triple negative breast carcinoma, urothelial carcinoma